MedTrace Logo

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

NCT05105672 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-12-28

No results posted yet for this study

Summary

This is a single-arm, single-center phase II clinical study to explore the efficacy and safety of sintilimab combined with concurrent chemoradiation therapy as treatment in women with locally advanced cervical cancer.

Conditions

  • Uterine Cervical Neoplasms
  • Sintilimab

Interventions

DRUG

Sintilimab

IV infusion

DRUG

Cisplatin

IV infusion

RADIATION

External Beam Radiotherapy (EBRT)

Undergo pelvic EBRT

RADIATION

brachytherapy

brachytherapy

Sponsors & Collaborators

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Longzhen Zhang, MD · The Affiliated Hospital of Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2023-03-01
Completion
2024-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05105672 on ClinicalTrials.gov